Duality Biotherapeutics, Inc. (HKG:9606)
Hong Kong · Delayed Price · Currency is HKD 173.10
-10.80 (-5.87%)
Sep 10, 2026, 11:59 AM HKT
Duality Biotherapeutics Revenue
Duality Biotherapeutics had revenue of 219.33M CNY in the half year ending June 30, 2026, a decrease of -78.06%. This brings the company's revenue in the last twelve months to 842.13M, down -61.20% year-over-year. In the year 2025, Duality Biotherapeutics had annual revenue of 1.85B, down -4.61%.
Revenue (ttm)
842.13M CNY
Revenue Growth
-61.20%
P/S Ratio
17.11
Revenue / Employee
3.65M CNY
Employees
231
Market Cap
16.63B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.85B | -89.52M | -4.61% |
| Dec 31, 2024 | 1.94B | 154.72M | 8.66% |
| Dec 31, 2023 | 1.79B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Duality Biotherapeutics News
- 12 days ago - Duality Biotherapeutics Earnings release: H1 2026 - Filings
- 12 days ago - DualityBio, Genentech Enter Global Deal To Develop Next-Gen ADCs - Nasdaq
- 5 months ago - Duality Biotherapeutics Slides: Investor presentation - Filings
- 5 months ago - Duality Biotherapeutics Earnings release: H2 2025 - Filings
- 5 months ago - Duality Biotherapeutics Annual report: H2 2025 - Filings